ReviewCurrent HIV/AIDS reports2025
Current and Investigational Biomarkers of Liver Disease in HIV-HBV Co-infection.
Review in Current HIV/AIDS reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCoinfection with HIV-HBV results in increased rate of liver disease progression through immune and metabolic dysfunction. Additional metabolic risks in ageing people with HIV (PwHIV) contribute to hepatic necroinflammation and fibrogenesis. There are now several blood-based and imaging non-invasive tests (NIT) that are increasingly available as an alternative to biopsy to estimate hepatic fibrosis. RECENT
findingsThere are few studies for NITs and fibrosis in PwHIV-HBV. Simple tests such as FIB-4 and APRI have poor diagnostic utility for significant fibrosis or disease monitoring in PwHIV-HBV. Transient elastography (TE) has less variability, and may be useful to exclude advanced fibrosis in patients with low viral load and normal liver enzymes. Combination TE and blood-based NITs with concordant results may be useful, but optimal diagnostic test thresholds have not been established. Interpretation of current NITs in PwHIV-HBV should consider context of use, along with clinical and biochemical variables that limit diagnostic accuracy.
Indexed as
Identifiers
41014390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.